Physician profile
Mark Charbonnet
NPI 1891718177
$17,262.48
in general payments reported to CMS, 2019-2025
51 companies · $2,624 in 2025
The $2,624 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,470 · 2020: $1,490 · 2021: $1,944 · 2022: $1,351 · 2023: $1,525 · 2024: $2,858 · 2025: $2,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,628 · Food and Beverage: $3,020 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,627.50 |
| Food and Beverage | $3,020.21 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,696.25 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,079.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,056.24 | 2019-2024 | Welireg, Keytruda, Lynparza |
| Amgen INC. | $957.91 | 2019-2023 | Evenity |
| E.R. Squibb & Sons, L.L.C. | $510.49 | 2020-2024 | Opdivo, Krazati |
| Janssen Biotech, INC. | $476.99 | 2019-2025 | Darzalex, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $452.58 | 2019-2025 | |
| Pfizer INC. | $377.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $377.17 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $376.12 | 2019-2025 | Somatuline Depot, Onivyde, Tazverik |
| Allergan, INC. | $250.00 | 2019 | |
| Genentech USA, INC. | $235.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $232.13 | 2019-2020 | |
| Puma Biotechnology, INC. | $206.54 | 2019-2024 | |
| Astellas Pharma US INC | $189.61 | 2021-2024 | Xtandi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Charbonnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.